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j ourna l homepage: www.e lsev ie r.com/ locate /ybcmdLetter to the EditorFig. 1. Serum IL-7 levels among controls and hemodialysis patients according to the
response to rhEPO therapy. Boxplot shows median value (horizontal line in box) and
ﬁrst and third quartiles (inferior and superior line of the box, respectively).IL-7 serum levels and lymphopenia in hemodialysis patients,
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There is a marked variability in the sensitivity to recombinant
human erythropoietin (rhEPO) therapy in hemodialysis patients, with
up to 10-fold variability in dose requirements to achieve correction of
anemia [1]. Approximately 5 to 10% of patients show a marked
resistance to rhEPO therapy [2]. This variability however remains
poorly clariﬁed. We showed that hemodialysis patients have lymphope-
nia [3], which results at least in part from a decrease in total circulating
CD3+ T-lymphocytes and affects both the CD4+ and the CD8+ T-cell
subsets.Wealsoobserved thatnon-responders to rhEPO therapypatients
presentwith a lower number of total lymphocyte and CD4+ T-cell counts,
when compared with responder patients. The lymphocyte depletion
found in hemodialysis patients, particularly in non-responders to rhEPO
therapy, could be related to an increased turnover of lymphocytes, to a
disturbance in lymphocyte homeostasis due to uraemia, and/or to
increased peripheral lymphocyte apoptosis associated with an activa-
tion stimulus.
Interleukin (IL)-7 has emerged as a key cytokine involved in con-
trolling the homeostatic turnover and the survival of resting memory
CD4+ T cells [4]. We hypothesized that the serum levels of this inter-
leukin could be related to the decreased number of total lymphocyte
and CD4+ T-cell counts that we have found in hemodialysis patients,
especially in non-responders to rhEPO therapy. In order to test this
hypothesis we selected 63 hemodialysis patients (36 males, 27
females; mean age 62.1±15.7) under rhEPO treatment, for a median
time period of 36 months. The hemodialysis patients included 32
responders and 31 non-responders to rhEPO therapy. Classiﬁcation of
hemodialysis patients, as responders or non-responders, was per-
formed in accordance with the European Best Practice Guidelines [5].
The rhEPO maintenance dose for responder patients was 90±58 U/kg
per week and for non-responders was 573±194 U/kg per week. The
two groups of patients were matched for age, gender, weight, body
mass index, mean time on hemodialysis, urea reduction ratio, urea
Ktv, and serum parathyroid hormone levels. Patients with auto-
immune disease, malignancy, hematological disorders, and acute or
chronic infection were excluded from the study. Healthy volunteers
(n=26), with normal hematological and biochemical values, without
any history of renal or inﬂammatory disease, were used as normal
controls. They werematched as far as possible for age and gender with
hemodialysis patients.
Serum levels of IL-7 were determined by the Quantikine high
sensitivity immunoassay (R & D Systems, Minneapolic, Minnesota,
USA) according to the manufacturer's recommendations.
No statistically difference was found between patients and
controls in total white blood cell count; however, hemodialysis
patients were lymphopenic [1.5±0.6 vs 2.2±0.7×109/L, pb0.05),1079-9796/$ – see front matter © 2008 Elsevier Inc. All rights reserved.
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circulating CD3+ T-lymphocytes [1.0 (0.7–1.3×109/L) vs 1.6 (1.0–
2.0×109/L), pb0.05] and both the CD4+ [0.7 (0.4–0.9×109/L) vs 1.0
(0.8–1.6×109/L), pb0.05] and the CD8+ [0.3 (0.1–0.4×109/L) vs 0.5
(0.3–0.7×109/L), pb0.05] T-cell subsets. When comparing respon-
ders and non-responders to rhEPO therapy, statistically signiﬁcant
differences were found for total lymphocyte [responders: 1.6
±0.5×109/L vs non-responders: 1.4×0.7×109/L, pb0.05] and CD4+
T-cell counts [responders: 0.8 (0.5–0.9×109/L) vs non-responders:
0.5 (0.4–0.9×109/L), pb0.05].
No signiﬁcant difference was found in serum IL-7 levels (pN0.05)
between hemodialysis patients [10.5 (7.4–13.5 pg/mL)] and healthy
controls [11.2 (7.2–16.0 pg/mL)], suggesting that the lymphopenia
found in these patients is not associated with increased serum levels
of IL-7. Moreover, no correlation between IL-7 serum levels and total
lymphocyte count (r=−0.21; p=0.11) was found. However, among the
two groups of patients, non-responders showed signiﬁcantly higher
IL-7 serum levels [non-responders: 12.0 (7.6–17.8 pg/mL) vs respon-
ders: 9.6 (6.1–11.5 pg/mL), pb0.05] (Fig. 1), suggesting a relationship
between the increased levels of this cytokine and decreased number
of total lymphocytes and CD4+ T-cell count in the non-responder
patients.
Increased IL-7 serum levels have also been described in other
clinical settings associated with lymphopenia, namely marrow
transplantation, HIV infection, chemotherapy treatment for cancer,openia in hemodialysis patients, non-responders to recombinant
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found in our lymphopenic patients could be related to T-cell depletion
[6]. Elevated serum IL-7 concentration may predict a lessened
response to rhEPO therapy.
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